Tenon Medical(R) Expands Sacro-Pelvic Fusion Portfolio with Strategic Asset Acquisition
Tenon Medical (NASDAQ:TNON) has acquired sacroiliac joint-specific assets from SiVantage, including their SImmetry庐 and SImmetry+鈩� technologies. The strategic acquisition transforms Tenon into a multi-product, multi-approach sacro-pelvic organization, expanding its portfolio across multiple approaches to sacro-pelvic anatomy.
The transaction brings critical technologies, intellectual property, and key leadership to Tenon, with SiVantage's co-founders joining as Chief Innovations Officer and Chief Commercial Officer. The deal structure includes an upfront cash component and equity issuance, with most consideration tied to future performance milestones. Integration is expected to complete in Q4 2025.
The acquisition immediately strengthens Tenon's product pipeline and is expected to contribute to revenue, supported by extensive clinical data demonstrating safety and performance in sacroiliac joint fusion procedures.
Tenon Medical (NASDAQ:TNON) ha acquisito asset specifici per l'articolazione sacroiliaca da SiVantage, inclusi la loro tecnologia SImmetry庐 e SImmetry+鈩�. Questa acquisizione strategica trasforma Tenon in un'organizzazione sacro-pelvica multi-prodotto e multi-approccio, ampliando il suo portafoglio attraverso diversi metodi per l'anatomia sacro-pelvica.
L'operazione porta a Tenon tecnologie fondamentali, propriet脿 intellettuale e figure chiave della leadership, con i co-fondatori di SiVantage che entrano a far parte come Chief Innovations Officer e Chief Commercial Officer. La struttura dell'accordo prevede una componente in contanti iniziale e l'emissione di azioni, con la maggior parte del corrispettivo legata a obiettivi di performance futuri. L'integrazione 猫 prevista per il quarto trimestre 2025.
L'acquisizione rafforza immediatamente la pipeline di prodotti di Tenon e si prevede contribuisca ai ricavi, supportata da dati clinici estesi che dimostrano sicurezza e performance nelle procedure di fusione dell'articolazione sacroiliaca.
Tenon Medical (NASDAQ:TNON) ha adquirido activos espec铆ficos para la articulaci贸n sacroil铆aca de SiVantage, incluyendo sus tecnolog铆as SImmetry庐 y SImmetry+鈩�. Esta adquisici贸n estrat茅gica convierte a Tenon en una organizaci贸n sacro-p茅lvica con m煤ltiples productos y enfoques, ampliando su portafolio a trav茅s de varias aproximaciones a la anatom铆a sacro-p茅lvica.
La transacci贸n aporta tecnolog铆as clave, propiedad intelectual y liderazgo fundamental a Tenon, con los cofundadores de SiVantage que se incorporan como Chief Innovations Officer y Chief Commercial Officer. La estructura del acuerdo incluye un pago inicial en efectivo y emisi贸n de acciones, con la mayor parte de la consideraci贸n vinculada a hitos de rendimiento futuros. Se espera que la integraci贸n se complete en el cuarto trimestre de 2025.
La adquisici贸n fortalece inmediatamente la cartera de productos de Tenon y se espera que contribuya a los ingresos, respaldada por extensos datos cl铆nicos que demuestran seguridad y desempe帽o en procedimientos de fusi贸n de la articulaci贸n sacroil铆aca.
Tenon Medical (NASDAQ:TNON)鞚� SiVantage搿滊秬韯� 觳滌灔甏�鞝� 鞝勳毄 鞛愳偘鞚� 鞚胳垬頄堨溂氅�, 鞐赴鞐愲姅 SImmetry庐 氚� SImmetry+鈩� 旮办垹鞚� 韽暔霅╇媹雼�. 鞚措矆 鞝勲灥鞝� 鞚胳垬搿� Tenon鞚� 雼れ牅頀�, 雼れ爲攴茧矔鞚� 觳滉敞-瓿皹 臁办鞙茧 鞝勴櫂霅橃柎 觳滉敞-瓿皹 頃措秬頃欖棎 雽�頃� 雼れ枒頃� 鞝戧芳氩曥潉 韽姼韽措Μ鞓れ棎 於旉皜頃橁矊 霅橃棃鞀惦媹雼�.
鞚措矆 瓯半灅毳� 韱淀暣 頃奠嫭 旮办垹, 歆�鞝� 鞛偘甓�, 欤检殧 毽崝鞁澊 Tenon鞐� 頃╇頃橂┌, SiVantage鞚� 瓿惦彊 彀诫鞛愲摛鞚� Chief Innovations Officer 氚� Chief Commercial Officer搿� 頃╇頃╇媹雼�. 瓯半灅 甑“電� 靹犽秷 順勱笀瓿� 欤检嫕 氚滍枆鞙茧 甑劚霅橂┌, 雽�攵�攵勳潣 雽�旮堨潃 頄ロ泟 靹标臣 氇╉憸鞐� 鞐半彊霅橃柎 鞛堨姷雼堧嫟. 韱淀暕鞚� 2025雲� 4攵勱赴鞐� 鞕勲霅� 鞓堨爼鞛呺媹雼�.
鞚措矆 鞚胳垬搿� Tenon鞚� 鞝滍拡 韺岇澊頂勲澕鞚胳澊 歃夓嫓 臧曧檾霅橂┌, 觳滌灔甏�鞝� 鞙淀暕 靾橃垹鞐愳劀鞚� 鞎堨爠靹标臣 靹彪姤鞚� 鞛呾頃橂姅 甏戨矓鞙勴暅 鞛勳儊 雿办澊韯半ゼ 氚旐儠鞙茧 毵れ稖鞐愲弰 旮办棳頃� 瓴冹溂搿� 旮半寑霅╇媹雼�.
Tenon Medical (NASDAQ:TNON) a acquis des actifs sp茅cifiques 脿 l'articulation sacro-iliaque de SiVantage, incluant leurs technologies SImmetry庐 et SImmetry+鈩�. Cette acquisition strat茅gique transforme Tenon en une organisation sacro-pelvienne multi-produits et multi-approches, 茅largissant ainsi son portefeuille 脿 travers plusieurs approches de l'anatomie sacro-pelvienne.
La transaction apporte 脿 Tenon des technologies essentielles, une propri茅t茅 intellectuelle et des dirigeants cl茅s, avec les cofondateurs de SiVantage rejoignant l'茅quipe en tant que Chief Innovations Officer et Chief Commercial Officer. La structure de l'accord comprend un paiement initial en esp猫ces et une 茅mission d'actions, la majorit茅 de la contrepartie 茅tant li茅e 脿 des jalons de performance futurs. L'int茅gration devrait s'achever au 4e trimestre 2025.
Cette acquisition renforce imm茅diatement la pipeline de produits de Tenon et devrait contribuer aux revenus, soutenue par des donn茅es cliniques 茅tendues d茅montrant la s茅curit茅 et la performance lors des proc茅dures de fusion de l'articulation sacro-iliaque.
Tenon Medical (NASDAQ:TNON) hat spezifische Verm枚genswerte f眉r das Sakroiliakalgelenk von SiVantage erworben, darunter deren SImmetry庐 und SImmetry+鈩� Technologien. Die strategische 脺bernahme verwandelt Tenon in eine multi-produkt- und multi-ansatz Sakro-Becken-Organisation und erweitert das Portfolio 眉ber verschiedene Ans盲tze der sakro-pelvinen Anatomie.
Die Transaktion bringt wichtige Technologien, geistiges Eigentum und Schl眉sselpersonen in die F眉hrungsebene zu Tenon, wobei die Mitgr眉nder von SiVantage als Chief Innovations Officer und Chief Commercial Officer eintreten. Die Struktur des Deals umfasst eine Vorauszahlung in bar und eine Aktienausgabe, wobei der Gro脽teil der Gegenleistung an zuk眉nftige Leistungsmeilensteine gebunden ist. Die Integration soll im 4. Quartal 2025 abgeschlossen sein.
Die 脺bernahme st盲rkt sofort Tenons Produktpipeline und wird voraussichtlich zum Umsatz beitragen, unterst眉tzt durch umfangreiche klinische Daten, die Sicherheit und Leistung bei Sakroiliakalgelenk-Fusionsverfahren nachweisen.
- Immediate revenue contribution expected from acquired core technology products
- Acquisition brings extensive clinical data and proven safety record
- Strategic addition of experienced leadership with SiVantage co-founders joining executive team
- Expanded product portfolio across multiple approaches to sacro-pelvic anatomy
- Performance-based deal structure minimizes upfront financial risk
- Potential share dilution from equity issuance component of transaction
- Integration risks and costs through Q4 2025
- Additional cash expenditure required for upfront payment
Insights
Tenon's acquisition of SiVantage assets strengthens its position in sacroiliac joint fusion with immediate revenue potential and expanded capabilities.
Tenon Medical has executed a strategic asset acquisition from SiVantage that significantly expands its sacroiliac (SI) joint fusion portfolio. This deal brings two key technologies - SImmetry庐 and SImmetry+鈩� - that enable Tenon to offer multiple approaches to address variable sacro-pelvic anatomy, transforming the company into a multi-product, multi-approach organization.
The transaction structure intelligently balances risk, featuring a modest upfront cash component and equity issuance, with most consideration tied to future performance milestones. This approach limits immediate financial burden while aligning incentives for long-term success.
What's particularly valuable is the acquisition of human capital alongside technology. SiVantage co-founders Wyatt Geist and Nate Grawey join Tenon's leadership as Chief Innovations Officer and Chief Commercial Officer, respectively. Geist brings significant intellectual property expertise with over 100 patents, while both executives contribute deep industry relationships that should accelerate commercial adoption.
The deal addresses a critical competitive differentiation in the rapidly evolving sacro-pelvic fusion market. While competitors focus primarily on fixation, Tenon emphasizes authentic biological fusion backed by clinical data. This positions the company's expanded portfolio as clinically distinctive rather than merely expanding product options.
Most importantly, management expects these technologies to contribute to revenue immediately, with integration activities scheduled for completion in Q4 2025. This acquisition represents a strategic pivot that could significantly accelerate Tenon's market position in a high-growth medical device segment.
~ SiVantage Portfolio Acquisition Enhances Tenon's Sacroiliac Joint Fusion Capabilities with a Unique Multi-Product, Multi-Approach Solution ~
~ Significant Enhancement of Tenon Medical's Commercial Leadership to Accelerate Growth Initiatives ~
~ Reinforces Tenon's Commitment to Fusion-Driven Innovation and Data-Backed Outcomes in a Rapidly Evolving Market ~
LOS GATOS, CA / / August 1, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical technology company dedicated to transforming care for patients with sacroiliac joint (SIJ) disorders, today announced it has acquired sacroiliac (SI) joint specific assets from SiVantage, a privately held startup company based in Tampa, Florida. This strategic asset acquisition includes SiVantage's SImmetry庐 and SImmetry+鈩� technologies expanding Tenon's SI portfolio across multiple approaches to the variable sacro pelvic anatomy. These differentiated technologies enable physicians to customize treatment plans for their patients using novel authentic fusion products backed by clinical data.
Transaction Highlights
Transaction moves critical technologies, intellectual property, and commercial leadership of SiVantage to Tenon Medical.
Core technology products are expected to contribute to revenue immediately.
Enhanced product pipeline is significantly strengthened, accelerating innovation and market readiness.
Supported by extensive clinical data, the integrated platform demonstrates a proven record of safety and performance.
Tenon is now a multi-product, multi-approach sacro-pelvic organization.
This strategic acquisition enhances Tenon's unique ability to meet the evolving needs of physicians and their patients.
SiVantage Co-Founders Wyatt Geist and Nate Grawey are joining Tenon's management team as Chief Innovations Officer and Chief Commercial Officer, respectively - bringing decades of medical device experience and relationships, further strengthening the Company's commercial leadership.
The Company now offers a modern, integrated portfolio spanning SI joint fusion, spinal fusion, and deformity adjuncts-each engineered to help deliver reliable fusion outcomes. While others focus on fixation, Tenon prioritizes what truly matters: biologic fusion.
Tenon's implants and instruments are designed not just to stabilize, but to actively promote bone healing, minimize loosening, and restore lasting structural stability.
Transaction structure includes a modest upfront cash component and an equity issuance representing a percentage of shares outstanding, with the majority of total consideration contingent upon achieving future performance milestones.
Integration activities will commence immediately and will be completed in Q4 2025.
Management Commentary
"The sacro pelvic fusion space is evolving very quickly. As our physician customers define their needs, Tenon Medical will deliver innovative solutions backed by clinical data to emerge as a leader in this high growth space." said Steve Foster, Chief Executive Officer of Tenon Medical. "With the addition of extraordinary people and a pipeline of innovative solutions, Tenon is now a multi-product and multi-approach sacro-pelvic organization that is poised for growth. We are laser focused on innovative solutions that deliver authentic fusion principals in a format with a strong safety profile backed by biomechanical and clinical data."
Wyatt Geist, CEO and Co-Founder of SiVantage and a recognized entrepreneur in the space with over one hundred patents to his name stated, "I am extremely excited to work with this data driven team to deliver exciting innovative technologies. It became clear in our early discussions with Tenon that we shared visions and values focused on collaborating with ethical partners to redefine sacroiliac fusion and deliver safe, effective solutions that enhance patient outcomes and provide unparalleled surgical reproducibility."
Nate Grawey, President and Co-Founder of SiVantage added, "Tenon's platform is THE perfect fit for SImmetry and the soon to be launched SImmetry+. This combined company will offer a differentiated portfolio that physicians want, administrators approve and payors value."
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran鈩� Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon is focused on three commercial opportunities with its System in the SI Joint market which include: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) Augmenting spinal fusion. For more information, please visit .
The Tenon Medical logo shown above, and Catamaran庐, PiSIF庐, CAT PiSIF庐, ETAD庐, Posterior Inferior Sacroiliac Fusion庐, CAT SIJ Fusion System庐, Catamaran SIJ Fusion System庐, Catamaran Inferior Posterior Fusion System庐, Catamaran Transfixation Fusion System庐, Catamaran Transfixation Fusion Device庐, SImmetry庐 are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+鈩� are also trademarks of Tenon Medical, Inc.
IR Contact:
Shannon Devine
203-741-8811
MZ North America
[email protected]
SOURCE: Tenon Medical, Inc.
View the original on ACCESS Newswire
FAQ
What assets did Tenon Medical (TNON) acquire from SiVantage?
How will the SiVantage acquisition affect Tenon Medical's market position?
What are the terms of Tenon Medical's acquisition of SiVantage assets?
Who are the key executives joining Tenon Medical from SiVantage?
When will the SiVantage integration be completed at Tenon Medical?
